Bilypsa (Saroglitazar) is a prescription medication primarily used to manage diabetic dyslipidemia, hypertriglyceridemia, and non-alcoholic fatty liver disease (NAFLD/NASH) in patients with Type 2 diabetes.Key Therapeutic UsesDiabetic Dyslipidemia: Lowers high triglyceride levels and improves overall cholesterol balance (reducing LDL and increasing “good“ HDL cholesterol).Blood Sugar Control: Assists in improving insulin sensitivity and stabilizing blood sugar levels in Type 2 diabetes.Fatty Liver Disease: Used for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) and NAFLD by helping to reduce fat build-up in the liver.Cardiovascular Risk Reduction: Helps reduce the risk of heart complications associated with uncontrolled lipids and diabetes.
Kuala Lumpur, Malaysia, Malaysia, 1